Skavis Biotec Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 22.67%
(FY 2022)
- Profit 2420.97%
(FY 2022)
- Ebitda 730.22%
(FY 2022)
- Net Worth 1.56%
(FY 2022)
- Total Assets -0.31%
(FY 2022)
About Skavis Biotec
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sejalbahen Gandhi, Neha Gandhi, Mehulkumar Gandhi, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397GJ2014PTC078614
- Company No.
078614
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Skavis Biotec Private Limited offer?
Skavis Biotec Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Common Disease Medicines, Injectable Products, Brain & Nervous System Drugs, Antiepileptic Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Anti Cancer Medicines, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Skavis Biotec?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sejalbahen Gandhi  | Director | 06-Feb-2014 | Current |
| Neha Gandhi | Director | 06-Feb-2014 | Current |
| Mehulkumar Gandhi | Director | 06-Feb-2014 | Current |
| Abhishekkumar Gandhi | Director | 06-Feb-2014 | Current |
Financial Performance of Skavis Biotec.
Skavis Biotec Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.67% increase. The company also saw a substantial improvement in profitability, with a 2420.97% increase in profit. The company's net worth moved up by a moderate rise of 1.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skavis Biotec?
In 2022, Skavis Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mymedical24 Private LimitedActive 3 years 7 monthsMehulkumar Gandhi and Abhishekkumar Gandhi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Skavis Biotec?
Unlock and access historical data on people associated with Skavis Biotec, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skavis Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skavis Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
